AMA designation advances access to Sensora, empowering clinicians with AI-powered cardiac care.
Eko Health has achieved a major milestone with the American Medical Association (AMA) granting a Category III CPT code for its Sensora platform, enabling proper documentation and broader adoption of its advanced tools for early heart disease detection.
Key Features of the Sensora Platform
- AI-driven detection: Identifies structural heart murmurs, arrhythmias, and low left ventricular ejection fraction (LVEF).
- High accuracy: Demonstrated 94.1% sensitivity and 84.5% specificity for detecting valvular heart disease.
- Integrated design: Works with the Core 500 digital stethoscope, combining auscultation and ECG technology.
“This milestone enables clinicians to use powerful, validated tools to improve outcomes in underserved communities,” said Connor Landgraf, CEO of Eko Health.
Transforming Cardiac Care
The FDA-cleared Sensora platform empowers providers with advanced screening capabilities:
- Accessible diagnostics: Brings early detection to both urban and remote areas.
- Ease of use: Utilizes familiar tools like the stethoscope to integrate seamlessly into practice.
- Better outcomes: Enables early intervention, reducing hospitalizations and complications.
Paul Friedman, MD, of Mayo Clinic, noted: “Detecting life-threatening conditions with a tool like the stethoscope can transform care delivery, especially in underserved areas.”
A Breakthrough Year for Eko Health
The CPT code follows FDA approval of the LVEF algorithm earlier in 2024, further advancing the platform’s capabilities. These innovations reinforce Eko Health’s role in revolutionizing cardiac care through AI.
Follow MEDWIRE.AI for updates on the latest developments in AI-driven technologies and their impact on patient care worldwide.
